Furthermore, we also found SMYD2 as a highly promising diagnostic biomarker for GC (AUC = 0.877), though its successful clinical implementation will require: large-scale multicenter validation of key diagnostic parameters including accuracy, specificity, inter-laboratory reproducibility, and systematic cost-benefit analyses comparing SMYD2 testing against existing diagnostic paradigms. Here, SMYD2 is linked to gastric cancer.